Chief and Co-Founder Executive Officer of Adamas.

Went, Ph.D., Chief and Co-Founder Executive Officer of Adamas. Related StoriesScientists suggest that Alzheimer's disease should be treated separatelyLewy Body Composite Risk Rating detects LBD and Parkinson's disease dementia in 3 minutesSynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy We are excited to expose the Nurelin system at the meeting today, and to offer an update on the previous preclinical and clinical studies that have resulted in our first Phase 2/3 study of Nurelin in Parkinson’s patients who knowledge levodopa-induced dyskinesia, stated Dr. Went. There are no medications presently approved for the treatment of levodopa-induced dyskinesia, there exists a significant unmet medical need thus. Nurelin is getting investigated as a therapeutic agent to address the non-electric motor symptoms of Parkinson’s disease, including fatigue..However, over the years of vaccine development, scientists have learnt that the path to finding a virus of appropriate strength is fraught with difficulties. This hurdle is usually compounded by the complexity of the dengue virus. Though there are only four different serotypes Also, the fairly high prices of mutation continuously means the virus evolve, and this plays a part in the fantastic diversity of the dengue infections circulating globally. Furthermore, in some full cases, the immune response developed following infection by among the four dengue viruses appears to increase the risk of severe dengue when the same specific is infected with any of the remaining three viruses.